drugset / Trial / NCT07090161

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT07090161

Phase 2 Recruiting 240 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Timeline

Start
2025-09-15
Primary completion
2026-10
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule

Indications